Browsing by Author "Falup-Pecurariu, C. (26535634100)"
Now showing 1 - 4 of 4
- Results Per Page
- Sort Options
- Some of the metrics are blocked by yourconsent settings
Publication Management of dystonia in Europe: A survey of the European network for the study of the dystonia syndromes(2016) ;Valadas, A. (25226081100) ;Contarino, M.-F. (6602814354) ;Albanese, A. (7101798303) ;Bhatia, K.P. (25958636400) ;Falup-Pecurariu, C. (26535634100) ;Forsgren, L. (7004808993) ;Friedman, A. (7401879559) ;Giladi, N. (7006084033) ;Hutchinson, M. (7201506609) ;Kostic, V.S. (57189017751) ;Krauss, J.K. (7202204228) ;Lokkegaard, A. (6506072792) ;Marti, M.J. (35445809200) ;Milanov, I. (55865025400) ;Pirtosek, Z. (6603412901) ;Relja, M. (7003318911) ;Skorvanek, M. (23478501900) ;Stamelou, M. (57208560010) ;Stepens, A. (23971707000) ;Tamás, G. (57189694613) ;Taravari, A. (36091985300) ;Tzoulis, C. (14032570400) ;Vandenberghe, W. (6603186020) ;Vidailhet, M. (7101610435) ;Ferreira, J.J. (36944021900)Tijssen, M.A. (7004162353)Background and purpose: Dystonia is difficult to recognize due to its large phenomenological complexity. Thus, the use of experts in dystonia is essential for better recognition and management of dystonia syndromes (DS). Our aim was to document managing strategies, facilities and expertise available in various European countries in order to identify which measures should be implemented to improve the management of DS. Methods: A survey was conducted, funded by the Cooperation in Science and Technology, via the management committee of the European network for the study of DS, which is formed from representatives of the 24 countries involved. Results: Lack of specific training in dystonia by general neurologists, general practitioners as well as other allied health professionals was universal in all countries surveyed. Genetic testing for rare dystonia mutations is not readily available in a significant number of countries and neurophysiological studies are difficult to perform due to a lack of experts in this field of movement disorders. Tetrabenazine is only readily available for treatment of dystonia in half of the surveyed countries. Deep brain stimulation is available in three-quarters of the countries, but other surgical procedures are only available in one-quarter of countries. Conclusions: Internationally, collaboration in training, advanced diagnosis, treatment and research of DS and, locally, in each country the creation of multidisciplinary teams for the management of dystonia patients could provide the basis for improving all aspects of dystonia management across Europe. European Journal of Neurology ©. - Some of the metrics are blocked by yourconsent settings
Publication Management of dystonia in Europe: A survey of the European network for the study of the dystonia syndromes(2016) ;Valadas, A. (25226081100) ;Contarino, M.-F. (6602814354) ;Albanese, A. (7101798303) ;Bhatia, K.P. (25958636400) ;Falup-Pecurariu, C. (26535634100) ;Forsgren, L. (7004808993) ;Friedman, A. (7401879559) ;Giladi, N. (7006084033) ;Hutchinson, M. (7201506609) ;Kostic, V.S. (57189017751) ;Krauss, J.K. (7202204228) ;Lokkegaard, A. (6506072792) ;Marti, M.J. (35445809200) ;Milanov, I. (55865025400) ;Pirtosek, Z. (6603412901) ;Relja, M. (7003318911) ;Skorvanek, M. (23478501900) ;Stamelou, M. (57208560010) ;Stepens, A. (23971707000) ;Tamás, G. (57189694613) ;Taravari, A. (36091985300) ;Tzoulis, C. (14032570400) ;Vandenberghe, W. (6603186020) ;Vidailhet, M. (7101610435) ;Ferreira, J.J. (36944021900)Tijssen, M.A. (7004162353)Background and purpose: Dystonia is difficult to recognize due to its large phenomenological complexity. Thus, the use of experts in dystonia is essential for better recognition and management of dystonia syndromes (DS). Our aim was to document managing strategies, facilities and expertise available in various European countries in order to identify which measures should be implemented to improve the management of DS. Methods: A survey was conducted, funded by the Cooperation in Science and Technology, via the management committee of the European network for the study of DS, which is formed from representatives of the 24 countries involved. Results: Lack of specific training in dystonia by general neurologists, general practitioners as well as other allied health professionals was universal in all countries surveyed. Genetic testing for rare dystonia mutations is not readily available in a significant number of countries and neurophysiological studies are difficult to perform due to a lack of experts in this field of movement disorders. Tetrabenazine is only readily available for treatment of dystonia in half of the surveyed countries. Deep brain stimulation is available in three-quarters of the countries, but other surgical procedures are only available in one-quarter of countries. Conclusions: Internationally, collaboration in training, advanced diagnosis, treatment and research of DS and, locally, in each country the creation of multidisciplinary teams for the management of dystonia patients could provide the basis for improving all aspects of dystonia management across Europe. European Journal of Neurology ©. - Some of the metrics are blocked by yourconsent settings
Publication MMSE and MoCA in Parkinson’s disease and dementia with Lewy bodies: a multicenter 1-year follow-up study(2016) ;Biundo, Roberta (8859828200) ;Weis, L. (55617107600) ;Bostantjopoulou, S. (55977734100) ;Stefanova, E. (7004567022) ;Falup-Pecurariu, C. (26535634100) ;Kramberger, M.G. (36544238400) ;Geurtsen, G.J. (57062897200) ;Antonini, A. (7102486937) ;Weintraub, D. (57203216133)Aarsland, D. (56222844000)The Mini-Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA) are the most commonly used scales to test cognitive impairment in Lewy body disease (LBD), but there is no consensus on which is best suited to assess cognition in clinical practice and most sensitive to cognitive decline. Retrospective cohort study of 265 LBD patients [Parkinson’s disease (PD) without dementia (PDnD, N = 197), PD with dementia (PDD, N = 40), and dementia with Lewy bodies (DLB, N = 28)] from an international consortium who completed both the MMSE and MoCA at baseline and 1-year follow-up (N = 153). Percentage of relative standard deviation (RSD%) at baseline was the measure of inter-individual variance, and estimation of change (Cohen’s d) over time was calculated. RSD% for the MoCA (21 %) was greater than for the MMSE (13 %) (p = 0.03) in the whole group. This difference was significant only in PDnD (11 vs. 5 %, p < 0.01), but not in PDD (30 vs. 19 %, p = 0.37) or DLB (15 vs. 14 %, p = 0.78). In contrast, the 1-year estimation of change did not differ between the two tests in any of the groups (Cohen’s effect <0.20 in each group). MMSE and MoCA are equal in measuring the rate of cognitive changes over time in LBD. However, in PDnD, the MoCA is a better measure of cognitive status as it lacks both ceiling and floor effects. © 2016, Springer-Verlag Wien. - Some of the metrics are blocked by yourconsent settings
Publication MMSE and MoCA in Parkinson’s disease and dementia with Lewy bodies: a multicenter 1-year follow-up study(2016) ;Biundo, Roberta (8859828200) ;Weis, L. (55617107600) ;Bostantjopoulou, S. (55977734100) ;Stefanova, E. (7004567022) ;Falup-Pecurariu, C. (26535634100) ;Kramberger, M.G. (36544238400) ;Geurtsen, G.J. (57062897200) ;Antonini, A. (7102486937) ;Weintraub, D. (57203216133)Aarsland, D. (56222844000)The Mini-Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA) are the most commonly used scales to test cognitive impairment in Lewy body disease (LBD), but there is no consensus on which is best suited to assess cognition in clinical practice and most sensitive to cognitive decline. Retrospective cohort study of 265 LBD patients [Parkinson’s disease (PD) without dementia (PDnD, N = 197), PD with dementia (PDD, N = 40), and dementia with Lewy bodies (DLB, N = 28)] from an international consortium who completed both the MMSE and MoCA at baseline and 1-year follow-up (N = 153). Percentage of relative standard deviation (RSD%) at baseline was the measure of inter-individual variance, and estimation of change (Cohen’s d) over time was calculated. RSD% for the MoCA (21 %) was greater than for the MMSE (13 %) (p = 0.03) in the whole group. This difference was significant only in PDnD (11 vs. 5 %, p < 0.01), but not in PDD (30 vs. 19 %, p = 0.37) or DLB (15 vs. 14 %, p = 0.78). In contrast, the 1-year estimation of change did not differ between the two tests in any of the groups (Cohen’s effect <0.20 in each group). MMSE and MoCA are equal in measuring the rate of cognitive changes over time in LBD. However, in PDnD, the MoCA is a better measure of cognitive status as it lacks both ceiling and floor effects. © 2016, Springer-Verlag Wien.
